![](/img/cover-not-exists.png)
Outcomes in patients with aggressive or refractory disease from REVEL, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Reck, Martin, Paz-Ares, Luis, Bidoli, Paolo, Cappuzzo, Federico, Dakhil, Shaker, Moro-Sibilot, Denis, Borghaei, Hossein, Johnson, Melissa, Jotte, Robert, Pennell, Nathan A., Shepherd, Frances A., TsaoLanguage:
english
Journal:
Lung Cancer
DOI:
10.1016/j.lungcan.2017.07.038
Date:
August, 2017
File:
PDF, 638 KB
english, 2017